WHO Releases New Clinical Management Guidelines for Ebola and Marburg (Filovirus) Diseases

The World Health Organization (WHO) has issued its first comprehensive set of clinical management guidelines for filovirus diseases, establishing a standardized framework for treating Ebola and Marburg virus infections. These new evidence-based recommendations, which include 16 distinct protocols, emphasize the necessity of early supportive care to improve patient survival rates and standardize medical responses during outbreaks, according to the official WHO announcement published on February 18, 2026.

Filoviruses, which cause severe and often fatal hemorrhagic fevers, have been responsible for 72 reported outbreaks in Africa since the discovery of the Marburg virus in 1967. Case fatality rates for these diseases vary widely, ranging from 25% to 90% depending on the specific virus strain and the quality of medical intervention provided, as noted in the WHO Ebola virus disease fact sheet. The new guidelines are intended to harmonize clinical approaches for health workers, administrators, and policy makers, particularly in regions currently managing active outbreaks, such as the ongoing struggle against the Bundibugyo virus in the Democratic Republic of the Congo.

Standardizing Care for Improved Survival

The core objective of the new guidelines is to provide frontline health workers with clear, actionable strategies to manage patients from initial presentation through recovery. Because there are currently no licensed vaccines or specific treatments for the Marburg virus, or for the Bundibugyo and Sudan strains of Ebola, the WHO stresses that optimized supportive care is the most effective tool for saving lives. According to WHO Director-General Dr. Tedros Adhanom Ghebreyesus, these guidelines represent a shift toward more diligent, holistic, and person-focused medical care designed to preserve human dignity during health emergencies.

The guidelines recommend several critical clinical interventions to reduce patient mortality:

• Laboratory Monitoring: The use of prioritized clinical laboratory tests to identify and address metabolic disruptions, including hypoglycemia, which can exacerbate the severity of the infection.
• Rehydration Protocols: Rapid assessment and treatment of dehydration, utilizing both oral and intravenous rehydration methods to stabilize patients.
• Managing Shock: The precise and early administration of intravenous fluids and vasoactive medications to treat shock, guided by continuous monitoring of vital signs and perfusion markers.
• Secondary Infection Control: Active screening for and treatment of concurrent bacterial infections, including bacterial sepsis, with appropriate antibiotic therapy.
• Post-Recovery Care: Implementation of structured after-care programs for survivors to support long-term well-being and mitigate risks associated with viral persistence in recovered patients.

Supporting Health Systems and Policy

Beyond individual patient care, the guidelines serve as an operational tool for health facility administrators. The document outlines the necessary infrastructure for effective outbreak response, including the adequate provision of biomedical equipment, laboratory support, and human resources. By standardizing these requirements, the WHO aims to ensure that healthcare facilities are better equipped to manage the surge in demand that characterizes filovirus outbreaks.

These recommendations were developed through extensive global expert consultations held in Brazzaville, synthesizing clinical data and lessons learned from recent outbreaks. This process ensures that the guidance reflects the most current scientific evidence available. The WHO previously issued specific guidance on therapeutics for Ebola virus disease, but this marks the first time that the clinical management of all filovirus diseases has been consolidated into a single, comprehensive document.

The Role of Evidence-Based Intervention

For clinicians on the front lines, the new guidelines provide a foundation for both immediate care and future research. According to the WHO, optimized supportive care is a vital prerequisite for clinical research evaluating potential antiviral treatments. By ensuring that patients receive a consistent standard of care, researchers can more accurately measure the efficacy of new therapeutic interventions in future clinical trials.

The release of these guidelines coincides with the lead-up to World Health Day 2026, which carries the theme “Together for health. Stand with science.” This campaign highlights the importance of scientific evidence as the foundation for protecting global health. As governments and health authorities integrate these recommendations into their national preparedness plans, the focus remains on reducing the socio-economic and psychological impacts that these outbreaks inflict on affected communities.

Implementation and Future Updates

The WHO encourages national health ministries to adopt these guidelines immediately to strengthen their existing outbreak response capabilities. While the document provides a comprehensive framework, it is designed to be used alongside existing operational tools and WHO guidance specific to local context. Health workers and policy makers can access the full technical document and accompanying implementation resources through the official World Health Organization portal.

The global health community awaits further data from ongoing field operations in the Democratic Republic of the Congo to assess the practical impact of these protocols in real-world settings. Readers are encouraged to monitor the WHO’s disease outbreak news page for updates on the current situation and further technical guidance. Please share your thoughts or questions regarding these new clinical standards in the comments section below.